Dexmedetomidine, Delirium, and Adverse Outcomes: Analysis of the STS Adult Cardiac Surgery Database

Abstract Background We tested the hypothesis that dexmedetomidine was associated with a reduced incidence of postoperative delirium (POD) and adverse outcomes in cardiac surgery patients from the Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database (ACSD) including the Adult Cardiac Anesthesiology subsection. Methods We identified 55905 patients in the STS ACSD who underwent cardiac surgery between July 2014 and December 2018. Using propensity score weighted regression analysis, we analyzed the effect of intraoperative dexmedetomidine (intraDex) on the primary (POD) and secondary outcomes (highest pain score on day 3 and at discharge, stroke, prolonged ventilation, postoperative intubation/reintubation, additional postoperative hours ventilated, renal failure, atrial fibrillation, and 30-day mortality). In separate propensity score weighted analyses, we examined the effect of postoperative dexmedetomidine (postopDex) on the highest postoperative pain score at discharge and 30-day mortality. Results The rate of intraDex use was 25.5% (n=13963), and its administration was associated with increased odds for POD (odds ratio [OR], 1.85; 95% CI, 1.60-2.13), a small higher average pain score on day 3 (difference in mean [MD], 0.08; 95% CI, 0.02 to 0.14), increased odds for postoperative intubation/reintubation (OR, 1.29; 95% CI, 1.12-1.48), and a small lower average pain score at discharge (MD, -0.31; 95% CI, -0.21 to -0.41). PostDex was associated with a small higher average pain score at discharge (MD, 0.27, 95% CI, 0.21 to 0.34), and higher odds for 30-day mortality (OR, 1.25, 95% CI, 1.07-1.46). Conclusions In this registry of cardiac surgical patients dexmedetomidine administration was associated with POD and adverse outcomes.